Medical microbiology

Global Clinical Laboratory Services Market Report 2022: Clinical Laboratories Played a Vital Role in Response to the Pandemic by Ramping Up Capacity to Meet the Increased Demand for Covid-19 Testing - ResearchAndMarkets.com

Retrieved on: 
금요일, 5월 27, 2022
Infectious Diseases, Biotechnology, Health, COVID-19 testing, COVID-19, Disease, Climate change, Clinical chemistry, Hospital, Proteomics, Health, Coronavirus, Automation, Genetics, Hospital Insurance and Diagnostic Services Act, Molecular biology, Medical microbiology, Awareness, Biotechnology, Compliance, Genomics, Adoption, CAGR, Human, Growth, Pharmaceutical industry, Pet

As Covid-19 financially disrupted healthcare organizations around the world, clinical laboratories of all sizes played a vital role in response to the pandemic by ramping up capacity to meet the increased demand for Covid-19 testing.

Key Points: 
  • As Covid-19 financially disrupted healthcare organizations around the world, clinical laboratories of all sizes played a vital role in response to the pandemic by ramping up capacity to meet the increased demand for Covid-19 testing.
  • The Covid-19 outbreak placed unprecedented demands on healthcare system in various countries with challenges of supply chain disruptions and heightened demand on health facilities.
  • The accelerated pace at which the novel coronavirus spread around the world saturated hospital capacity and exposed the deficiencies in the public health system.
  • This segment currently accounts for a 21.6% share of the global Clinical Laboratory Services market.

New Customer Installation of LUMICKS' z-Movi® Cell Avidity Analyzer Confirms Value of Cell Avidity Measurement in Leading Labs Studying Biomarkers of Immune Oncology

Retrieved on: 
목요일, 4월 21, 2022
Molecule, Drug development, Institute of technology, Z movie, Technical University of Munich, Hygiene, Research, TUM, Immunotherapy, Biomarker, Cell, Technology, Immune system, Laboratory, TCR, Immunology, General manager, Leonard M. Miller School of Medicine, School, Biology, Medical microbiology, Vaccine

AMSTERDAM, April 21, 2022 /PRNewswire/ -- LUMICKS, a leading life science tools company that develops instruments for dynamic single-molecule and cell avidity analysis, today announced that it has completed a new installation of its revolutionary z-Movi® Cell Avidity Analyzer in the lab of Prof. Dirk Busch, Professor of Medical Microbiology, Immunology and Hygiene at the School of Medicine, Technical University of Munich (TUM). The installation demonstrates the expanding interest in measuring cell avidity as a key biomarker in understanding immune oncology.

Key Points: 
  • The installation demonstrates the expanding interest in measuring cell avidity as a key biomarker in understanding immune oncology.
  • The z-Movi instrument measures the avidity between immune cells and their targets, enabling researchers to identify the most potent immunotherapeutic effector cells.
  • We are very pleased to contribute to a better scientific understanding of how measuring cell avidity can uncover critical biomarkers that help advance immune oncology efforts worldwide.
  • Similarly, the z-Movi Cell Avidity Analyzer enables the measurement and selection of immune cells based on their real-time interactions with target cells.

New Customer Installation of LUMICKS' z-Movi® Cell Avidity Analyzer Confirms Value of Cell Avidity Measurement in Leading Labs Studying Biomarkers of Immune Oncology

Retrieved on: 
목요일, 4월 21, 2022
Molecule, Drug development, Institute of technology, Z movie, Technical University of Munich, Hygiene, Research, TUM, Immunotherapy, Biomarker, Cell, Technology, Immune system, Laboratory, TCR, Immunology, General manager, Leonard M. Miller School of Medicine, School, Biology, Medical microbiology, Vaccine

AMSTERDAM, April 21, 2022 /PRNewswire/ -- LUMICKS, a leading life science tools company that develops instruments for dynamic single-molecule and cell avidity analysis, today announced that it has completed a new installation of its revolutionary z-Movi® Cell Avidity Analyzer in the lab of Prof. Dirk Busch, Professor of Medical Microbiology, Immunology and Hygiene at the School of Medicine, Technical University of Munich (TUM). The installation demonstrates the expanding interest in measuring cell avidity as a key biomarker in understanding immune oncology.

Key Points: 
  • The installation demonstrates the expanding interest in measuring cell avidity as a key biomarker in understanding immune oncology.
  • The z-Movi instrument measures the avidity between immune cells and their targets, enabling researchers to identify the most potent immunotherapeutic effector cells.
  • We are very pleased to contribute to a better scientific understanding of how measuring cell avidity can uncover critical biomarkers that help advance immune oncology efforts worldwide.
  • Similarly, the z-Movi Cell Avidity Analyzer enables the measurement and selection of immune cells based on their real-time interactions with target cells.

Co-Diagnostics, Inc. Makes Strategic Additions to Scientific Advisory Board

Retrieved on: 
목요일, 3월 17, 2022
ARUP Laboratories, Company, Private Securities Litigation Reform Act, Medicine, PSLRA, Principal, Tron Lightcycle Power Run, Johns Hopkins University, Biochemistry, DNA, College, Medical microbiology, Growth, List of pathologists, Pathology, M.D, College of American Pathologists, Research, SEC, Doctor of Philosophy, Risk, BioMérieux, Coronavirus Scientific Advisory Board (Turkey), CSO, ASM, Laboratory, CEO, Severe acute respiratory syndrome coronavirus 2, U.S. Securities and Exchange Commission, RNA, Johns Hopkins School of Medicine, Kyoto University, Infectious Diseases Society of America, SALT, Security (finance), Technology, Infection, Acquisition, Time, American Academy, University of Utah, SAB, Yale University, Saliva, Annual report, University, Division, Pharmaceutical industry, Management, Medical device

SALT LAKE CITY, March 17, 2022 /PRNewswire/ --Co-Diagnostics, Inc.(Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, is pleased to announce today that it has made several strategic additions to its Scientific Advisory Board ("SAB").

Key Points: 
  • SALT LAKE CITY, March 17, 2022 /PRNewswire/ --Co-Diagnostics, Inc.(Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, is pleased to announce today that it has made several strategic additions to its Scientific Advisory Board ("SAB").
  • Dwight Egan, CEO of Co-Diagnostics, remarked, "We are honored to have such talented and renowned industry leaders advising Co-Diagnostics.
  • Dr. Wittwer, cofounder and CSO of Idaho Technology/BioFire since 1990 and board chairman of BioFire during its acquisition by bioMerieux in 2014, is professor emeritus of Pathology at the University of Utah.
  • She has worked in the United States and Japan directing strategic investments in new technology.

Seegene appoints Dr. Glen Hansen as Head of Medical Affairs of U.S. subsidiary

Retrieved on: 
목요일, 3월 17, 2022
Molecular diagnostics, University, Hennepin County Medical Center, Patient, Medical microbiology, Multimedia, Science, University of Saskatchewan academics, Adoption, COVID, Medical director, Medical Affairs Bureau, University of Minnesota School of Dentistry, Leadership, CEO, Immunology, Medical device, Management, Microbiology

SEOUL, South Korea, March 17, 2022 /PRNewswire/ -- Seegene Inc. (KQ 096530), South Korea's leading molecular diagnostics company, today announced the appointment of Glen Hansen, Ph.D., D(ABMM), FCCM, as the Head of Scientific and Medical Affairs of its United States subsidiary, Seegene Technologies .

Key Points: 
  • SEOUL, South Korea, March 17, 2022 /PRNewswire/ -- Seegene Inc. (KQ 096530), South Korea's leading molecular diagnostics company, today announced the appointment of Glen Hansen, Ph.D., D(ABMM), FCCM, as the Head of Scientific and Medical Affairs of its United States subsidiary, Seegene Technologies .
  • Dr. Hansen has decades of real-world and clinical experience as a microbiologist specializing in molecular diagnostics and medical microbiology.
  • Prior to joining Seegene, he was the Medical Director of the Microbiology and Molecular Diagnostics Laboratory at Hennepin County Medical Center in Minneapolis and the University of Minnesota School of Medicine.
  • Dr. Hansen graduated with honors from the University of Saskatchewan where he earned dual bachelor's degrees in Microbiology and Immunology.

Theralase® Demonstrates Proof-of-Concept for Canadian-Made COVID-19 Vaccine

Retrieved on: 
월요일, 2월 7, 2022
News, Light, Trial of the century, GLOBE, Forward-looking statement, Department, Daou Technology Inc., Medical microbiology, TSX Venture Exchange, PHAC, CRA, Research, National Microbiology Laboratory, Company, University of Manitoba, Risk, Bacteria, CSS, Technology, PDC, Department of Medical Microbiology (Schering AG), Patient, University, Public Health Agency, TLT, UM, Animal, TSX, Coronavirus, Head, Reactive oxygen species, Oxidative stress, Public Health Agency of Canada, Cancer, Virus, Interim, Influenza, Biological hazard, Cell, COVID-19, Pharmaceutical industry, Vaccine

Under the terms of the agreement, Theralase and PHAC are collaborating on the research, development and optimization of a COVID-19 vaccine by inactivating the SARS-CoV-2 virus with Theralases light-activated PDC, TLD-1433.

Key Points: 
  • Under the terms of the agreement, Theralase and PHAC are collaborating on the research, development and optimization of a COVID-19 vaccine by inactivating the SARS-CoV-2 virus with Theralases light-activated PDC, TLD-1433.
  • These results have now laid the groundwork for the next phase of the CRA, which is evaluating the Theralase COVID-19 vaccine in the ability to prevent animals from contracting COVID-19, when exposed to the virus.
  • The research also demonstrates that the Theralase platform is extremely versatile, with an ability to be applicable to a wide range of enveloped viruses.
  • Based on this encouraging data, the Company intends to move forward in the research, development and commercialization of the Theralase COVID-19 vaccine, subject to the required regulatory approval.

COPAN Diagnostics Announces Another Giant Step in the Evolution of Artificial Intelligence in Clinical Microbiology

Retrieved on: 
수요일, 1월 19, 2022
ID, Patient, Technology, News, AST, Robotics, Kaiser Permanente, Algorithm, IUO, Growth, TAG, CLSI, Collection, Directory, Opacity, Health, Medical microbiology, Review, WASP, Time, Culture, Heel, Multimedia, AI, Mark (given name), McFarland, Chemistry (relationship), Software, FDA, Artificiality, Physician, Medical device, Microbiology, Colibri

COPAN launches PhenoMATRIX TAG, AI software that automatically selects isolated colonies on plated media for picking.

Key Points: 
  • COPAN launches PhenoMATRIX TAG, AI software that automatically selects isolated colonies on plated media for picking.
  • This innovation in laboratory automation rapidly and precisely ensures that the correct isolated and/or pure aggregated colonies are automatically chosen for work-up,"said COPAN Diagnostics' CEO Norman Sharples.
  • COPAN Diagnostics' Workflow Specialist and LEAN Six Sigma Blackbelt, Rosalind Russell discussed the impact that PhenoMATRIX TAG has on laboratory workflow.
  • WASPLab is a highly efficient, modular, scalable, and customizable specimen processing and culture work-up system for Clinical Microbiology.

Colibri™ Automated Specimen Workup Instrument by COPAN Receives FDA 510(k) Clearance for Use with MALDI-TOF Mass Spectrometry Analyzers

Retrieved on: 
목요일, 1월 6, 2022
Time, AI, View, Intelligence, Artificial intelligence, Attention, Growth, WASP, Software, Workflow, Medical microbiology, MS, Gram-positive bacteria, Chemistry (relationship), Laboratory, AST, Robotics, McFarland, Algorithm, FDA, IUO, Pressure, Opacity, Solution, Multimedia, CLSI, Collection, Medical device, Colibri, Microbiology

MURRIETA, Calif., Jan. 5, 2022 /PRNewswire/ -- COPAN Diagnosticsis proud to announce the FDA clearance of Colibri, an automated processor that is a complementary part of WASPLab, COPAN's full laboratory automation system.

Key Points: 
  • MURRIETA, Calif., Jan. 5, 2022 /PRNewswire/ -- COPAN Diagnosticsis proud to announce the FDA clearance of Colibri, an automated processor that is a complementary part of WASPLab, COPAN's full laboratory automation system.
  • FDA cleared Colibri provides time and labor savings by automating a crucial step in diagnostic Microbiology.
  • COPAN's Colibri is unlike any other instrument in Microbiology.It automatically picks isolated colonies for further workup and investigations.
  • About COPAN Full Laboratory Automation WASPLab:
    WASPLab is a highly efficient, modular, scalable, and customizable specimen processing and culture workup system for clinical Microbiology.

1910 Genetics Appoints Dr. Jennifer Leeds as Independent Board Director

Retrieved on: 
수요일, 12월 15, 2021
Health, Genetics, General Health, Research, Science, Pharmaceutical, Biotechnology, Failure, Board of directors, Immunology, Infection, Board, University of Wisconsin–Madison, Genetics, Harvard Medical School, Business development, Cornell University, COVID-19, Female, Director, AI, Probability, Drug discovery, Medical microbiology, CEO, Novartis, Artificial intelligence, Neuroscience, Drug development, Â, Patent, NIBR, Multimedia, University, Technology, Lead, Pharmaceutical industry, Management, Microbiology, Doctor of Philosophy

1910 Genetics, a biotechnology company integrating artificial intelligence (AI), computation and biological automation to improve drug development, today announced that Jennifer Leeds, Ph.D., will join as an independent member of the companys Board of Directors.

Key Points: 
  • 1910 Genetics, a biotechnology company integrating artificial intelligence (AI), computation and biological automation to improve drug development, today announced that Jennifer Leeds, Ph.D., will join as an independent member of the companys Board of Directors.
  • With two decades in the pharmaceutical sector, Dr. Leeds joins 1910 Genetics with extensive experience in drug discovery and development, including strategic partnerships and evaluation of novel targets, platforms and technologies.
  • View the full release here: https://www.businesswire.com/news/home/20211215005296/en/
    Jennifer Leeds, Ph.D. appointed to Board of Directors at 1910 Genetics.
  • Before joining the Board of 1910 Genetics, Dr. Leeds held several leadership positions over her 19 years at NIBR.

Tillotts Pharma AG announces that DIFICLIRTM (fidaxomicin) is recommended for the treatment of Clostridioides difficile infection (CDI) by ESCMID

Retrieved on: 
수요일, 12월 8, 2021
Health, Infectious Diseases, Clinical Trials, Research, Pharmaceutical, Science, Medical microbiology, Disease, CDI, European Society of Clinical Microbiology and Infectious Diseases, Infectious Diseases Society of America, News, Risk factor, ESCMID, Recurrence, Goldenberg, Dis, Clostridioides difficile infection, Microbiota, Infection, PMID, Acquisition, Plasma protein binding, Clostridioides, Meta-analysis, ECDC, IDSA, Patient, IBD, Consultant, Mortality, OTC, Human, Tesco international operations, Clostridium difficile, Systematic review, Vancomycin, European Centre for Disease Prevention and Control, Lancet, University, Tablet, Guideline, Society, Wes Tillott, Fidaxomicin, CDAD, Health care, MD, Adult, RNA, Clinical trial, Trial of the century, Vaccine, Pharmaceutical industry, DIFICLIRTM, Tillotts, Zeria, DIFICLIRTM, TILLOTTS, ZERIA

Despite the endemic nature of C. difficile in many healthcare settings, sustained clinical cure and prevention of recurrence are achievable treatment goals for CDI.

Key Points: 
  • Despite the endemic nature of C. difficile in many healthcare settings, sustained clinical cure and prevention of recurrence are achievable treatment goals for CDI.
  • European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults.
  • Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial.
  • Tillotts Pharma AG, part of the Japanese Zeria Group, is a fast-growing specialty pharma company with over 300 employees in Switzerland and abroad.